Search for information about a product,
therapeutic area or event

Search

Media, investors, advocacy organizations and others, please contact us here.

Medical Information FSGS

FILSPARI (sparsentan) – Decreases in Hemoglobin

Learn more
Medical Information FSGS

FILSPARI (sparsentan) – Mechanism of Action and Pharmacology

Learn more
Medical Information FSGS

FILSPARI (sparsentan): Elevated Liver Transaminases and Hepatic Safety Results

Learn more
Medical Information FSGS

FILSPARI (sparsentan) – Concomitant Medications Included in Clinical Trials

Learn more
Medical Information FSGS

FILSPARI (sparsentan) – Changes in Blood Pressure and Hypotensive Events

Learn more
Medical Information FSGS

FILSPARI (sparsentan) – Safety and Efficacy in Focal Segmental Glomerulosclerosis (FSGS)

Learn more
Medical Information FSGS

FILSPARI (sparsentan) – Use with Diuretics in IgA Nephropathy and FSGS

Learn more
Medical Information FSGS

FILSPARI (sparsentan) – Transitioning from ACEi/ARB Treatment to Sparsentan in Clinical Trials

Learn more
Medical Information FSGS

FILSPARI (sparsentan) – Dosing and Administration in Clinical Trials

Learn more
Medical Information FSGS

FILSPARI (sparsentan) – Safety in Clinical Trials

Learn more
Medical Information FSGS

FILSPARI (sparsentan) – Edema and Congestive Heart Failure

Learn more
Medical Information FSGS

FILSPARI (sparsentan) – Drug-Drug Interactions

Learn more
Medical Information FSGS

FILSPARI (sparsentan) – Pharmacokinetic Profile

Learn more